NCT07515027Recruiting
Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery
Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 7 Apr 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Shanghai Chest Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07515027
What you commit to
- Study type: Interventional
- Planned participants: 204
- From 7 Apr 2026 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous esophageal or gastric surgery;
- Conversion to open surgery;
- Acupuncture treatment received within 1 month prior to enrollment.
Other illness
- Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function;
- Subjects with cognitive dysfunction or psychological disorders;
- Hypersensitivity to acupuncture or any study medications;
- Severe infection or history of surgery around the acupuncture sites;
Other
- Pregnant or lactating women;
- Long-term opioid use;
Who the study is looking for
- Age ≥ 18 years;
- American Society of Anesthesiologists (ASA) physical status I-III;
- Body mass index (BMI) 18-30 kg/m²;
- Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection;
- Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3;
- Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities;
- No infection around the acupuncture sites;
- Voluntary written informed consent provided by the subject.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.